logo UKRAIN®

can be reversed



Nowicky Pharma (FZE)

P.O. Box 48748,
Dubai Marina
United Arab Emirates

No: 01-01-02951

Inventor and patent owner
Dr. Wassil Nowicky
Margaretenstr. 7, A-1040 Vienna, Austria
Tel.: (+43 1) 586 12 23 Fax: (+43 1) 586 89 94



UKRAIN is produced from alkaloids from the plant Chelidonium majus L. (greater celandine) and the pharmaceutical Thiotepa. Both of these ingredients are approved as drugs and are in wide clinical use. However UKRAIN is much less toxic than its ingredients, while at the same time having a more powerful anti-carcinogenic effect. Gas chromatography has shown that there is no free (i.e. unbound) Thiotepa in the final product UKRAIN.



    • is toxic against cancer cells at the therapeutic dose but not against healthy cells
    • accumulates at the site of the tumour very rapidly after injection
    • brings about the encapsulation of larger tumours through anti-angiogenesis (the inhibition of new blood vessels at the tumour site), thereby increasing operability
    • regenerates the immune system

    363 cancer patients with 47 different types of tumour were treated with UKRAIN between September 1997 and January 2003 at the Villa Medica Clinic (Edenkoben, Germany) under the medical direction of Dr. Aschhoff. These patients had already exhausted conventional means of therapy without success, and because of relapse and/or continued progression of the disease, UKRAIN therapy was undertaken. The following rates of full remission were achieved: breast cancer 31%, colorectal cancer 16.7%, bronchial adenocarcinoma 7.7%, small-cell bronchial carcimoma 21%, astrozytoma (brain tumor) 66.6%, neuroblastoma 60%, seminoma (testicular cancer) 75%, bladder carcinoma 50% (181, 189).


    The powerful anti-cancer properties of the drug have also been shown in numerous examples of patients treated outside the hospital environment, including cases of remission brought about by UKRAIN that have lasted 19 years after therapy. At the same time, randomised clinical studies confirm that these therapeutic successes were no coincidence but due to the anti-tumour effects of UKRAIN.


    To date UKRAIN has been tested on more than 100 cancer cell lines and has proved its malignotoxic effect against all of them, including pancreatic cancer cell lines and cell lines which were resistant to the chemotherapy drug Cisplatin, as well human tumour transplants. At the doses at which UKRAIN kills cancer cell lines, healthy cells are not attacked. The concentration of UKRAIN at which it would be toxic for normal cells is 100 times higher than the concentration which kills all cancer cell lines (12, 190).